CAMP4 Therapeutics Corp (CAMP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.41-1.78%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — EPS loss narrows toward -$0.79 in 2026: FY26 EPS -1.04 vs -0.79 target.
CAMP4 is growing revenue fast, about 45% next year. It made a big deal with GSK. The company added a new board member. These show progress and new chances.
CAMP4 still loses money and missed earnings recently. Its profit per share is negative. The company faces high risk and uncertain profits.
The market expects about 45% revenue growth next year. Our fair value is near the current price, showing limited upside.
Breaks if: EPS loss worsens beyond -0.79 in FY26
Breaks if: YoY revenue growth falls below 44.9% in FY26
Breaks if: Loss of key partnerships or leadership changes hurt growth
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
CAMP represents a speculative growth investment, as it operates in the healthcare sector with potential upside from clinical trials. However, the current thesis state is cautious due to recent performance and high risks.
The market seems to price in a premium compared to peers, reflecting expectations of optionality despite the company's loss-making status. This premium may not be fully justified given the recent decline in company quality and mixed management execution.
Fundamentals are likely to remain under pressure due to the company's loss-making nature and high risk. Management is working on key priorities, but recent financial performance has been below industry standards, indicating potential challenges ahead.
The long-term thesis hinges on management's ability to successfully initiate clinical trials and maintain a cash runway. Additionally, external factors such as sector performance and economic conditions will play a significant role in shaping future outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings report showed a miss. This miss is a significant threat to the company's outlook. The company has not provided new support for its thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Overall, CAMP's situation is complex with a mix of potential and risk factors. The next few quarters will be critical for assessing its trajectory. Not investment advice.